June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Intravitreal Bevacizumab or Ranibizumab for Rubeosis Iridis - 3 years follow up
Author Affiliations & Notes
  • Joao Nassaralla
    Retina and Vitreous, Instituto de Olhos de Goiania, Goiania, Brazil
    Faculdade de Ciências da Saúde, UnB, Brasilia, Brazil
  • João Nassaralla
    Medicine, UNIFENAS, Belo Horizonte, Brazil
  • Belquiz Nassaralla
    Cornea and Cataract, IOG, Goiania, Brazil
  • Footnotes
    Commercial Relationships Joao Nassaralla, None; João Nassaralla, None; Belquiz Nassaralla, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 444. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao Nassaralla, João Nassaralla, Belquiz Nassaralla; Intravitreal Bevacizumab or Ranibizumab for Rubeosis Iridis - 3 years follow up. Invest. Ophthalmol. Vis. Sci. 2013;54(15):444.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine and compare whether intraocular bevacizumab and ranibzumab decreases RI in patients with neovascular glaucoma (NVG).

Methods: The study included 72 eyes of 64 patients with secondary NVG due to proliferative diabetic retinopathy (n=60) or ischemic vessel occlusion (n=12). All patients received an intraocular injection (IOI) of 1.25 mg of bevacizumab (IB) or ranibizumab (IR), from November 2007 to October 2012 at the Goiania Eye Institute. Intraocular injection was performed in topical anaesthesia either in the anterior chamber (n=58) or via pars plana intravitreally (n=14). RI was investigated prospectively by iris biomicroscopy. An expanded informed consent with an off-label use waiver and explanation letter was reviewed with all patients. The IOI was performed under sterile conditions in an operating theatre and was performed with proximetacaine (Anestalcon® - Alcon - Brazil) topical anesthesia and the injection did via pars plana. The follow up

Results: Degree of RI decreased significantly (p<0.01) within 1 week after application of both drus. The improvement was maintained for at least 4 weeks when was did PRP. After 3 years only 5 eyes (3 IB and 2 IR) development reccurent RI, when was did more injection and more PRP. The two drugs are about equal in their effectiveness. An inflammatory response with fibrinous reaction and pseudohypopyon was observed in three cases (2 bevacizumab and 1 with ranibizumab) one day after surgery. The reaction persisted only 2 days. However, that cost differences for those receiving treatment are major at about $40 per injection for Avastin and $2,000 per injection for Lucentis.

Conclusions: The preliminary conclusion is that the two drugs are about equal in their effectiveness.

Keywords: 503 drug toxicity/drug effects • 568 intraocular pressure • 700 retinal neovascularization  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.